Stay updated on Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page
- Check4 days agoChange DetectedA notice was added announcing NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check11 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 Forbidden page; the study record remains inaccessible.SummaryDifference0.2%

- Check18 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check38 days agoChange DetectedThe page now displays a 403 Forbidden screen instead of the study details, indicating the study record cannot be accessed at this time.SummaryDifference20%

- Check60 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6 on the page, representing a minor maintenance update to the entry.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a minor update to the document version. No new content or data changes are specified.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page.